Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer

Lignende værker

• MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib
  af: Ninomiya, Kiichiro, et al.
  Udgivet: (2018)
• Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR-mutant lung cancer with HIF-1α/TGF-α expression
  af: Nishii, Kazuya, et al.
  Udgivet: (2021)
• Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report
  af: Go Makimoto, et al.
  Udgivet: (2022-05-01)
• Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo
  af: Kudo, Kenichiro, et al.
  Udgivet: (2017)
• Efficacy of multimodal treatment for leptomeningeal metastases in a lung cancer harboring an EGFR mutation
  af: Morichika, Daisuke, et al.
  Udgivet: (2016)